Among early-stageHER2-nonamplified BC, a tendency of improved OS could be observed among HER2-low positive in comparison with the HER2-0 cohort, while no significant survival difference could be found between the two cohorts regardless of HR expression. This evidence concerns the gene ERBB2 and breast cancer.